Skip to main
CVRX

CVRx (CVRX) Stock Forecast & Price Target

CVRx (CVRX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CVRx is a commercial-stage medical device company with a proprietary platform technology, Barostim, designed to treat cardiovascular diseases by leveraging the power of the brain to address the imbalance of the Autonomic Nervous System. Despite a slight decrease in active accounts in Q4/26, the company expects to add approximately three territories per quarter and grow net accounts in the high single digits. Additionally, the recent implementation of Category I CPT codes should reduce reimbursement friction and improve commercial access, which could expand the total addressable market for Barostim. Overall, with strong financial results and market potential, we maintain a positive outlook on CVRx's stock.

Bears say

CVRx is seeing revenue growth and gross margin outperform their initial 2026 projections. However, the company's Q1 OpEx was higher than expected, and their number of active sites is slightly lower than anticipated. There is potential for future growth with the BENEFIT-HF trial, but current productivity levels and a decline in the company's comparative multiple lead to a lowered price target of $10.

CVRx (CVRX) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CVRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CVRx (CVRX) Forecast

Analysts have given CVRx (CVRX) a Buy based on their latest research and market trends.

According to 3 analysts, CVRx (CVRX) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CVRx (CVRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.